AbbVie Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-100.0% vs price
Base Case (Median)
-100.0% vs price
Bull Case (75th pct.)
-100.0% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $-12.66 | -100.0% | High (40%) |
| PE Comparable | $3.76 | -100.0% | Medium (25%) |
| EV/EBITDA | $4.47 | -100.0% | Medium (20%) |
| EV/FCF | $23.39 | -99.9% | Medium (20%) |
| Earnings Power Value | $8.93 | -100.0% | Medium (50%) |
Based on 5 out of 8 methods, ABBV.BA appears overvalued at the current price of $34100.00. The base case fair value of $4.47 implies 100.0% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.